- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04834388
Studying Anakinra to Reduce Secondary Brain Damage After Spontaneous Haemorrhagic Stroke (ACTION)
Anakinra in Cerebral Haemorrhage to Target Secondary Injury Resulting From Neuroinflammation - a Phase II Clinical Trial
Spontaneous intracerebral haemorrhage (sICH) is the deadliest stroke subtype yearly affecting over 6000 patients in the Netherlands. Treatment options are very limited. Inflammation plays a vital role in the development of sICH-related secondary brain injury (SBI). Within 4 hours after sICH onset, blood components and thrombin induce the release of cytokines and other inflammatory molecules, with subsequent microglial activation, blood brain barrier (BBB) damage and the formation of perihaematomal oedema (PHO). Among the released cytokines, interleukin 1 beta (IL-1β) has a pivotal role. Recombinant human interleukin-1 receptor antagonist (IL-1Ra, anakinra) effectively antagonizes IL-1β through competitive binding to the IL-1 receptor. Anakinra is available for treatment of rheumatoid arthritis, other inflammatory diseases and has been studied in acute sepsis. We hypothesize that anakinra safely reduces SBI after sICH, and that its effect is dose-dependent.
Objective: To determine the effect of high-dose versus low-dose anakinra compared to standard medical management on oedema extension distance (OED) determined with MRI on day 7±1. Second, to study the safety profile of anakinra. Furthermore, to assess its effect on 1) serum inflammatory markers IL-1β, IL-6, hsCRP, neutrophil and total white blood cell counts at day 1, 3 and 7 compared to baseline; 2) DCE-MRI measurement of BBB transfer constant (Ktrans) on day 7±1, and; 3) to estimate an effect on functional outcome in patients with sICH.
Study design: Multicentre, prospective, randomized, three-armed (1:1:1) trial with open label treatment and blinded end-point assessment (PROBE design) .
Study population: 75 patients with supratentorial sICH admitted within 8 hours after symptom onset.
Intervention: Patients will receive anakinra in either a high dose (loading dose 500mg i.v., followed by infusion with 2mg/kg/h over 3 days; n=25) or in a low dose (loading dose 100mg s.c.., followed by subcutaneous administration of 100mg twice a day for 3 days; n=25), started within 8 hours of symptom onset. The control group (n=25) will receive standard medical management.
Main study parameters/endpoints: Primary objective is to test whether anakinra reduces subacute perihaematomal oedema after sICH, measured as OED on MRI at day 7±1.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Floris H.B.M Schreuder, MD PhD
- Phone Number: +31650155755
- Email: floris.schreuder@radboudumc.nl
Study Contact Backup
- Name: Maaike P. Cliteur, MD
- Phone Number: +31650155723
- Email: maaike.cliteur@radboudumc.nl
Study Locations
-
-
-
Nijmegen, Netherlands
- Recruiting
- Radboudumc
-
Contact:
- Radboudumc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years;
- Supratentorial non-traumatic ICH confirmed by CT, without a confirmed causative lesion on admission CT-angiography (e.g. aneurysm, AVM, DAVF, cerebral venous sinus thrombosis) or other known underlying lesion (e.g. tumour, cavernoma);
- Minimal intracerebral haemorrhage volume of 10 mL;
- Intervention can be started within 8 hours from symptoms onset;
- Patient's or legal representative's informed consent.
Exclusion Criteria:
- Severe ICH, unlikely to survive the first 72 hours (defined as Glasgow Coma Scale score < 6 at time of consent);
- Confirmed or suspected haemorrhagic transformation of an arterial or venous infarct;
- Planned neurosurgical haematoma evacuation;
- Severe infection at admission, requiring antibiotic treatment;
- Known active tuberculosis or active hepatitis;
- Use of immunosuppressive or immune-modulating therapy at admission (see 15.1 Appendix A);
- Neutropenia (Absolute Neutrophil Count (ANC) <1.5 x 109/L );
- Pre-stroke modified Rankin Scale score ≥ 3;
- Pregnancy or breast-feeding;
- Standard contraindications to MRI (see 15.2 Appendix B);
- Known prior allergic reaction to gadolinium contrast or one of the constituents of its solution for administration;
- Known allergy to anakinra or other products that are produced by DNA technology using the micro-organism E. coli;
- Live vaccinations within the last 10 days prior to this ICH;
- Severe renal impairment (eGFR <30ml/min/1.73m)
- Active malignancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anakinra High dose
500mg i.v.
loading dose, followed by continuous iv infusion with 2mg/kg/h over 3 days
|
Anakinra treatment is started within 8 hours of symptom onset
Other Names:
|
Experimental: Anakinra Low dose
100mg s.c.
loading dose, followed by subcuteanous administration of 100mg twice daily for 3 days.
|
Anakinra treatment is started within 8 hours of symptom onset
Other Names:
|
No Intervention: Standard care
Standard care group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perihematomal oedema
Time Frame: 7 days after ICH onset
|
Measured as Oedema Extension Distance (OED/EED)
|
7 days after ICH onset
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events of special interest (AESI) and serious adverse events (SAE)
Time Frame: 90 days
|
90 days
|
|
Blood brain barriere leakage
Time Frame: 7 days
|
Measured as Ktrans on DCE-MRI
|
7 days
|
Levels of serum inflammatory markers
Time Frame: 7 days
|
IL-1β, IL-6, hsCRP, neutrophil and total white blood cell counts
|
7 days
|
Functional outcome
Time Frame: 90 days
|
Ordinal shift in functional outcome (comparing the intervention group to the controls), assessed with the modified Rankin Scale (mRS) at 3 months.
This is a six point scale in which a score of 0 means no symptoms at all, a higher score means more impairment, and a score of 6 means the participant is dead.
|
90 days
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL76607.091.21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracerebral Hemorrhage
-
Wake Forest University Health SciencesActive, not recruitingStroke Hemorrhagic | Intracerebral Hemorrhage | Cerebral Edema | Intracerebral Hemorrhage, Hypertensive | Intracerebral Hemorrhage IntraparenchymalUnited States
-
Tongji HospitalUnknown
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
Beijing Tiantan HospitalBeijing Friendship Hospital; RenJi Hospital; Qilu Hospital of Shandong University and other collaboratorsRecruitingSpontaneous Intracerebral HemorrhageChina
-
University Hospital, Basel, SwitzerlandSwiss Heart FoundationActive, not recruitingIntracerebral Hemorrhage (ICH)Switzerland
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
AegisCN LLCCompletedIntracerebral Hemorrhage (ICH)United States
-
CellMed AG, a subsidiary of BTG plc.TerminatedIntracerebral Hemorrhage (ICH)Germany
-
Tang-Du HospitalRecruitingIntracerebral Hemorrhage;Circulating ExosomesChina
Clinical Trials on Anakinra
-
University of AthensCompletedCoronary Artery Disease | Inflammation | Rheumatoid ArthritisGreece
-
Virginia Commonwealth UniversityAmerican Heart AssociationCompleted
-
Weill Medical College of Cornell UniversitySwedish Orphan BiovitrumWithdrawnCovid19 | Mechanical Ventilation Complication | Cytokine StormUnited States
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)Withdrawn
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)Withdrawn
-
Virginia Commonwealth UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart FailureUnited States
-
National Institute of Neurological Disorders and...CompletedMultiple SclerosisUnited States
-
National Institute of Arthritis and Musculoskeletal...CompletedImmune System Diseases | Autoimmune Connective Tissue DisorderUnited States
-
National Institute of Allergy and Infectious Diseases...TerminatedEczema | Atopic Dermatitis | Allergic Disease | Anakinra | KineretUnited States